Swiss drugmaker Novartis has terminated a mid-stage study testing its drug ​Fabhalta in patients with a ‌serious kidney condition, citing "strategic considerations", according to a federal clinical trials registry.

Log in or sign up to comment.

No comments yet.

← Back to stories

Create FREE account

or login to continue

Signup with GoogleSignup with GitHubSignup with BlueskySignup with Blacksky
Sign up with email

Already have an account? Log in